PrP
C is a cell-surface glycoprotein with an essential role in the pathogenesis of transmissible neurodegenerative prion diseases (1;2). According to the prion hypothesis, a misfolded, pathogenic form of the protein (PrP Sc ), is the sole constituent of transmissible prions (3;4) , but the molecular details and required environs for the misfolding are incompletely understood. As would be expected for a glycosyl-phosphatidyl-inositol (GPI)-anchored protein with N-linked glycans, PrP C is observed at the outer leaflet of the plasma membrane, the endpoint of the secretory route. The half-time at the plasma membrane is fairly short, since the protein may undergo shedding or endocytic internalisation (5) (6) (7) (8) (9) . Thus, PrP C can be encountered throughout the secretory and endocytic routes and is also able to leave cells via exosomes derived from multivesicular endosomes (10) . In agreement with this, studies of the subcellular distribution of PrP C in mammalian brain have identified localization to the outer cell membrane, in the Golgi apparatus, and in endosomal vesicles (11;12) . However, others have found that PrP C is not solely associated with membranes, but, in some sub-populations of neurons, is localized to the cytoplasm (13;14) . In line with the latter observations, transgenic mice expressing PrP carrying a Cterminal GFP tag demonstrated intense cytoplasmic fluorescence from a limited number (approx 1%) of the neurons in certain brain areas, such as the hippocampus (15) . Immunohistochemical detection of intracellular, possibly cytoplasmic, PrP has also been reported from large mononuclear cells in the gut wall of sheep (16) and from enteric neurons in mice (17) . The recent observations of pronounced cytoplasmic aggregation of PrP in pancreatic beta-cells of rats prone to development of diabetes mellitus, provide a perplexing example of non-standard PrP localization, in non-neuronal cells (18) .
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The flexibility observed in the subcellular localization of PrP C has been suggested to be a requirement for normal functions of the protein (14;19;20) , but how cytoplasmic and nuclear variants arise has not been established. Cytoplasmic PrP could be a result of retro-translocation from the endoplasmic reticulum (ER), as part of an unfolded protein response (21) (22) (23) , or from attenuated ER import of PrP under conditions of lumenal stress in the ER (24;25) . The finding of intact ER-targeting signal sequences on cytoplasmic PrPs (25;26) , favors the latter mechanism, namely a reduced ER-import of PrP, possibly due to saturation of the ERtranslocation machinery, or an overload of unfolded proteins within the ER. However, no signs of stress or pathology could be detected in neurons of wild-type mice expressing cytoplasmic PrP (14) , which led to the suggestion that the cytoplasmic appearance of PrP could constitute a physiologically relevant, but minor, pathway for the protein.
Forced cytoplasmic expression of PrP in transgenic mice (22) and in the nematode Caenorhabditis elegans (27) resulted in neurodegenerative disease, suggesting that toxic mislocalization of PrP could be part of the pathogenic mechanism in prion diseases (28) . However, transgenic mice expressing cytoplasmic PrP, on a PrP-null background, developed cerebellar atrophy, but were resistant to experimental prion infection (29) , suggesting that cytoplasmic PrP is unlikely to serve as substrate for prion replication. Furthermore, data obtained from transgenic mice expressing an anchorless secretory PrP show that, although these mice accumulate PrP-containing amyloid plaques upon challenge with PrP Sc , they fail to develop clinical prion disease (30) . Thus, membraneattached PrP appears to be a prerequisite for development of prion-derived neurodegeneration.
In eukaryotes, ribosomes bind specifically to linear mRNAs carrying a 7-methylguanosine 5'-end cap and slide along the mRNA in the 5' -3' direction until they encounter the first start codon (AUG), from which the protein translation starts exclusively. Therefore, eukaryotic mRNAs are generally monocistronic. However, deviations from this standard principle have been reported, in which protein translation is initiated at alternative start codons either up or downstream from the primary AUG. The best characterized mechanism is known as contextdependent leaky ribosomal scanning (LRS) (31) . This cap-dependent mechanism is particularly operative when the optimal (5'-GCCRCCaugG-3') sequence context surrounding the first AUG codon is compromised, most notably at positions R -3 (R = purine, A or G, but optimally G) and G +4 (32;33) .
In this work, we report that in a cell culture system, sheep PrP mRNA displays a tendency to allow alternative translation initiation through LRS. Met 17 serves as an internal in-frame alternative start codon giving rise to PrP with a severely shortened ERtargeting peptide.
While the LRS mechanism is active in sheep PrP, it appears to occur much less in mouse PrP (34) . The molecular explanation and possible patho-physiological relevance of these observations in relation to PrP function await further studies. Interestingly, during the review process of this paper, observations of cytoplasmic PrP similar to some of those described herein, were reported for human and hamster PrP (35) .
MATERIALS AND METHODS

Construction
of plasmids-The construction of plasmids coding for PrP* and GFP PrP*, has been described previously (36 9 beads/ml. The paramagnetic beads were covalently coated with P4 as follows: beads were washed and resuspended in 55 µl 100 mM sodium phosphate buffer, pH 7.4, complemented with 15 µg P4 and 0.1% bovine serum albumin (BSA). After thorough mixing by vortexing, 35 µl 3 M ammonium sulphate was added. After incubation for 48 h at RT with gentle mixing, the beads were washed four times in PBS with 0.1% BSA. A sub-sample of 1 ml cell lysate was added to a pellet of coated beads, corresponding to 27 µl bead suspension, and incubated at RT for 30 min before washing three times in PBS. The resulting bead pellet was boiled for 5 min in 20 µl of SDS sample buffer. The beads were removed by use of a magnet and the supernatants electrophoresed as previously described. Coomassie-stained bands of interest were excised by scalpel for in-gel digestion in 20 µl of 50 mM ammonium bicarbonate, pH 7.8 with either 0.1 µg of trypsin (Promega, Madison, WI, USA) or 0.2 µg chymotrypsin (Sigma-Aldrich Norway A/S, Oslo, Norway). The enzymatic digests were purified using ZipTip µ-C18 (Millipore, Billerica, MA, USA) and the eluates dried using a Speed Vac concentrator (Savant, Holbrook, NY, USA). The peptides were dissolved in 0.5 µl 0.2% trifluoroacetic acid/acetonitrile (2:1) and mixed with 0.5 µl 20 mg/ml α-cyano-4-hydroxycinnamic acid in 0.2 % aqueous trifluoroacetic acid/acetonitrile (2:1). The samples were applied to a stainless steel sample holder and, after drying, introduced into the ULTRAFLEX II (Bruker Daltonics, Bremen, Germany) MALDI-TOF/TOF mass spectrometer and analyzed in the MS mode (for generation of peptide mass fingerprints) as well as in the TOF/TOF mode (for fragmentation analysis). MS spectra were transformed into peak lists using the software FlexAnalysis version 2. (50/50) was prepared in 50 mM Tris, 150 mM NaCl, 0.05% Triton X-100, pH 7.5 and 1% BSA as described by the manufacturer and incubated on a roller overnight at 6°C. Aliquots of 20 µl Protein G slurry were added to the samples and mixed on a roller for 3 h at 6°C. Thoroughly washed agarose pellets were boiled in SDS sample buffer for 5 min before centrifugation at 13 000 rpm for 2 min at RT. Supernatants were subjected to SDS-PAGE and Western blotting. Western immune blots were developed with mouse TrueBlot ULTRA, HRP anti-mouseIgG (Bioscience) after incubation with monoclonal primary antibodies, while the polyclonals anti-SP and R505 were developed with anti-rabbit IgG conjugated to alkaline phosphatase (BioRad).
Microscopy-Cells transiently transfected with un-tagged PrP were grown on glass coverslips (Assistent) in a 24 well plate (Sarstedt). After 24 h, cells were fixed in PBS supplemented with Ca 2+ (0.02 mM) and Mg 2+ (0.2 mM) (PBS + ) and 3.7% formaldehyde before permeabilization with 0.1 % Triton X-100, blocking in 5 % fat-free dried milk in PBS and incubation for 1 h with primary antibody P4 in PBS with 1 % fat-free dried milk. After washing with PBS, cells were incubated with goat-anti-mouse secondary antibody labelled with alexa-488 fluorochrome (Molecular Probes) before confocal microscopy. Cells transiently transfected with various GFP PrP constructs were grown on glass slides (LabTek II Chambered coverglass, Nunc), and analyzed after 24 h by the fluorescence protease protection assay (41) . Briefly, cells were washed with KHM buffer (110 mM potassium acetate, 20 mM HEPES, 2 mM MgCl 2 ) at 37°C and treated with either digitonin (40 µM) to permeabilize the plasma membrane, or trypsin, (4 mM) or both, in the presence or absence of 1% (vol/vol) Triton X-100. Non-saturated images were captured by a Plan-Apochromat 63/1.4 oil objective in a Zeiss laser scanning confocal microscope (Zeiss Axiovert 200M fluorescent inverted microscope, equipped with a LSM 510 laser confocal unit and 488 nm argon laser and 546 nm helium/neon laser, Carl Zeiss, Jena, Germany).
Crude preparations from sheep brainPurification of synaptosomal/microsomal membrane fractions from sheep brain was performed as described by (42) . Briefly, immediately after euthanasia, the brain was removed and 40 g was homogenized in a Dounce all-glass homogenizer in 200 ml of ice-cold bicarbonate-buffer containing 0.32 M sucrose, 0.5 mM KCl, 1 mM MgCl 2 , 1 mM NaHCO 3 and protease inhibitor tablets (Complete, Hoffman-La Roche AG, Basel, Schweiz).
After initial low-speed centrifugations and rehomogenization, supernatants were combined and centrifuged at 100,000g on a 0.85 M sucrose cushion at 4°C for 1 h. The resulting pellet was highly enriched in PrP and used for Western blot analysis.
RESULTS
Sheep PrP fused with green fluorescent protein (GFP)-
We have generated a large number of sheep GFP PrP gene constructs, in which GFP is positioned between amino acid 43 and 44 in the Nterminal region of PrP (Fig. 1) . Our initial observations indicated remarkable differences in intracellular trafficking of both un-tagged PrP and GFP PrP fusion variants. These enticed us to conduct a more systematic study, particularly of the region surrounding the start codon triplet (AUG), including the Kozak sequence. Constructs (PrP* and GFP PrP*) with compromised Kozak sequence were expressed in N2a cells, giving diffuse intracellular staining, indicating cytoplasmic localization of these PrP variants (Figs. 2A, 3A) . For comparison, wild-type PrP and GFP PrP (intact Kozak sequence) displayed a typical cell surface localization, with some of the protein localized to intracellular vesicular compartments. Western blot analysis revealed that mono-and di-glycosylated forms of PrP prevailed when PrP with intact Kozak sequence was expressed, while for PrP*, unglycosylated and mono-glycosylated forms dominated. An N-terminal fragment of about 8 kDa was faintly visible in untreated cells, and more clearly visible after treatment with the proteasome inhibitor LC (Fig. 2B) . Next, we expressed a construct lacking the region coding the ER-targeting signal peptide ( (Fig. 3A) .
GFP PrP
The differential localization of GFP PrP fusion protein variants was verified by the fluorescence protease protection assay. Cells expressing GFP PrP with a typical plasma membrane appearance lost the corresponding fluorescent signal after 30 sec of trypsin treatment (Fig. 3B) , indicating that the protein was attached to the outer leaflet of the plasma membrane.
GFP PrP*, however, was trypsin resistant, even after 2 min of treatment, but the fluorescence was reduced after digitoninmediated permeabilization of the plasma membrane, and was rapidly abolished upon combined treatment with trypsin, digitonin and Triton X-100 (Fig. 3B) . This indicates that GFP PrP* was localized intracellularly, largely in a freely diffusible form, and unprotected by endomembranes that are resistant to digitonin treatment. Furthermore, proteinase resistant aggregates were not observed.
We also investigated biochemically the intracellular fate of newly synthesized GFP PrP variants. PrP normally enters the lumen of the ER co-translationally, to obtain one or two Nglycan groups. Such variants are clearly the predominant products for GFP PrP in N2a cells (Fig. 4A and B, lane 1) . The variant lacking the entire ER signal peptide (lane 3) was expressed as a full-length, non-glycosylated variant, but also appeared as a truncated doublet derived from the N-terminal region. Similarly, this doublet was the dominant feature for GFP PrP* (lane 2), which also displayed a full-length non-glycosylated variant, and only faint bands for mono-and di-glycosylated GFP PrP. The doublet was recognized by the P4 antibody, but not by antibodies recognizing epitopes situated closer to the C-terminus of PrP (36) . Epitope mapping (Figs. 4 and 6 ) and MALDI-MS/MS analysis (Fig. S1 , Supplementary Material) enabled us to narrow the C-termini of the truncation doublet to residues 104 and 115, with an error margin of 2-3 residues. Since, these proteolytic products were prominent in the variant lacking the signal sequence, and also clearly observable for the wild-type construct (Fig. 4A) , we could not deduce whether their appearance for GFP PrP* resulted from compromised ER import or from successful ER import, followed by retrograde transport to the cytoplasm. We therefore investigated whether the proteolytic fragments could be detected by an anti-SP antibody. The doublet bands obviously contained the SP, indicating that GFP PrP* did not encounter the ER signal peptidase prior to proteolytic processing in the cytoplasm (Fig. 4B) . Treatment of cells with the proteasome inhibitor LC, led to a slight increase in full length un-glycosylated forms (Fig. 2B and 4B , arrowheads) and a weak decrease in staining of the N-terminal doublet, indicating that proteasomal degradation of full length GFP PrP could occur.
Alternative translation initiation at Met 17 (Fig. 5A, left  panel) , but even more so in Western blot analysis, in which the characteristic truncation doublet with intact anti-SP reactivity could be detected (Fig. 5B, lane 2, all panels) . This observation allowed us to conclude that the truncation doublet starts at Met 17 which preserves the anti-SP epitope except for the Nterminal residue Thr 16 (T). Thus, removal of Met 1 elicited production of cytoplasmic PrP, starting at Met 17 . However, the definitive experiment would be to test whether removal of Met 17 could block this minor pathway for sheep PrP. Indeed, expression of the GFP PrP M17T plasmid gave rise to a membranous, pericellular fluorescence signal (Fig. 5A) , but, importantly, it resulted in complete removal of the truncation doublet (Fig. 5B, (Fig.  5A) , or from GFP PrP in Western blots (Fig. 5B,  lane 4, upper and lower panels) . This was investigated because this amino acid substitution theoretically corresponds to an improvement in the sequence surrounding Met 1 , as the +5T is substituted with the slightly more ideal +5C. However, the assays used here failed to detect any consistent effect of this change. Notably, detection of immunoprecipitated samples with the anti-SP antibody, displayed a lower sensitivity as compared with the P4 antibody, which appears extremely efficient in Western blotting. This difference in sensitivity is evident when comparing lanes 4 and 5 in Fig. 5B . Thus, direct detection of the truncation doublet by P4 in cell lysates (Fig.  5B, upper panel) proved to be a reasonably sensitive and very simple assay for the detection of cytoplasmic GFP PrP, driven by constructs described herein.
Failure to provoke alternative translation start in mouse PrP-The alternative translation initiation we observed for sheep PrP led us to investigate whether the same phenomenon occurs for PrP from another species. We therefore used mouse GFP PrP constructs, which are only a few amino acids different from the sheep constructs at the insertion-site for GFP (Fig. 6A , details in methods). As shown in Fig. 6A , the ERtargeting SP in mouse PrP is 2 residues shorter than the sheep equivalent, with additional coding differences at 8 positions out of 15. For mouse PrP, Met 15 corresponds to Met 17 in sheep PrP and could theoretically serve as an internal translational initiator. Two constructs were made, one with a wild-type Kozak sequence surrounding Met 1 ( GFP moPrP) and one ( GFP moPrP*) with a severely compromised Kozak sequence (Fig. 6A) . Expression of these constructs failed to reveal any differences in cellular distribution of the fluorescence signal (Fig. 6B ) and in Western blots (Fig. 6C) . Since the P4 antibody does not detect mouse PrP, it was substituted by an anti-GFP antibody in this assay. This antibody also detects the Nterminal truncation doublet in sheep PrP with adequate sensitivity. However, no traces of the truncation doublet could be found after expression of the mouse constructs, indicating that if a cytoplasmic variant of GFP PrP was expressed, its level was below the sensitivity of our assay. The somewhat weaker Western blot signal for GFP moPrP*, as compared with GFP moPrP (Fig. 6C) , could indicate that the compromised Kozak sequence resulted in a general reduction of translation efficiency. Interestingly, Western blot analysis of crude sheep brain homogenates allows detection of N-terminal fragments that correspond well with those observed in cell culture (Fig. 7, lane  6) . However, discriminating these from fragments generated by other PrP processing events remains challenging.
In summary, we have demonstrated that in N2a cells, sheep PrP mRNA with a proper Kozak sequence around the first start codon allows alternative initiation of translation through LRS. The alternative start codon results in PrP with a severely shortened ER SP that remains in the cytoplasm and consequently is subject to proteolytic breakdown. This mechanism, detected for sheep PrP, occurs at a much lower level for mouse PrP, when this protein is expressed in the same cell culture system.
DISCUSSION
In this work, we investigated whether mechanisms related to protein translation initiation could contribute to the generation of cytoplasmic PrPs. In order to address this question, we generated sheep PrP constructs, in particular GFP PrP chimeras in which the nucleotide sequence surrounding the first initiator codon (Met 1 ) was compromised. This nucleotide sequence, known as the Kozak sequence, has been comprehensively studied for its influence on protein translation (31) . A peculiarity of the constructs that lack an intact Kozak sequence, was that they resulted in a shift in cellular localization of PrP, with a dispersed, intracellular, fluorescence signal, accompanied by a characteristic doublet of bands in Western blots ( GFP PrP*), containing two N-terminal fragments of PrP (36) . Further analysis using a polyclonal anti-SP antibody (43) , identified full length PrP and an Nterminal truncation doublet, neither of which had been processed by the ER residing signalpeptidase. The signal peptidase cleaves Cterminally of Cys 24 in sheep PrP and destroys the anti-SP epitope. PrP starting at Met 17 , the alternative down-stream translation start, still harbors the epitope for the anti-SP antibody. Cultivation of transfected cells in the presence of the proteasome inhibitor LC resulted in a slight increase of cytoplasmic full length PrP with a corresponding reduction of the truncation doublet (Fig. 4B ), in agreement with previous observations of proteasomal degradation of cytoplasmic PrP species (26) .
The N-terminal PrP doublet was also clearly detectable when the Kozak sequence was intact ( GFP PrP). This finding triggered us to consider whether the truncation doublet signified a minor, constitutive pathway in sheep PrP, generating cytoplasmic PrP. Of note, expression of GFP PrP revealed no indication of cytoplasmic PrP as judged by fluorescence microscopy, which reflects the relatively low sensitivity of this assay in searching for minor protein pathways. As pointed out by Levine and co-workers (34) a minor protein pathway must reach 10-20% of the total amount, before direct detection of mislocalized GFP-tagged targets by fluorescence is possible. Fluorescence protease protection was used to confirm the gross cellular localization of the two variants, GFP PrP and GFP PrP*, with an extracellular signal from GFP PrP (Fig. 3 A and B) and an intracellular, slowly diffusible trypsin-sensitive form for GFP PrP*. Taken together, these data prompted the question whether the internal methionine found at residue 17 (Met 17 ) in ruminant PrPs could function as an alternative in-frame initiation site for translation. In support of this possibility, mutational substitution of Met 17 , maintained the membranous PrP signal and completely abolished the N-terminal doublet, while substitution of Met 1 , in the presence of Met 17 produced a picture indistinguishable from that seen with the GFP PrP*, with dispersed intracellular PrP-signal and a dominant Nterminal truncation doublet in Western blots. These observations, in particular the effects seen by sequence manipulations surrounding Met 1 , are exactly those which would be expected with the LRS mechanism.
Context-dependent LRS is a well characterized mechanism (23) . A capindependent mechanism based upon internal ribosomal entry sites (IRES), originally described for viral mRNAs with long and complex 5' non-translated regions, has also been proposed to play a role in cellular mRNAs (44) , but the evidence has been questioned (45) . An analysis of more than 22 200 human mRNAs showed that only 37.4 % of the genes adhered to the optimal AUG sequence context and that 12.5 % of the genes lacked both R -3 and G +4 which could potentially lead to strong LRS (46) . Low level LRS is difficult to detect and is probably a vastly underestimated phenomenon. The compromised sequence surrounding Met 1 in the GFP PrP* plasmid apparently provoked strong LRS and correspondingly led to a dominating shift in PrP localization as compared with the same construct, but with wild-type Kozak sequence, GFP PrP, in which the expected membranous localization of PrP was seen. In ruminant and mink PrPs the second amino acid is V, while in primates and rodents it is A. To investigate whether this difference could be part of the LRS mechanism, a GFP PrP V2A construct was made. However, this substitution did not influence the occurrence of LRS as judged by detection of the N-terminal doublet ( Fig. 5A and B) .
The observations with sheep PrP inspired further search for LRS in PrP mRNA from another species. Plasmids encoding mouse PrP carrying GFP in the N-terminal tail, almost identical to the sheep GFP-tagged PrPs described here, were acquired, one with compromised ( GFP moPrP*), and one with wildtype ( GFP moPrP), Kozak sequences (Fig. 6A) . However, no difference could be observed between the two constructs, neither by fluorescence microscopy nor in Western immune blots (Fig. 6 B and C) . This was in contrast to the shift in cellular localization seen for the sheep PrP, indicative of substantial species variation in this phenomenon. In mouse PrP, Met 15 could theoretically serve as an internal in-frame translational initiation site analogous to Met 17 in sheep PrP. Our data, however, suggest that LRS appears less frequently in mouse PrP. The mechanism behind this species difference is not known, but could be related to structural nuances between the mRNAs that could influence the fidelity of start codon selection. Regardless, our data with GFP moPrP agree with those from previous analysis of LRS in mouse PrP in which a very sensitive luciferase-based assay revealed that LRS occurs at a low level in mouse PrP. However the assay used herein is probably insufficiently sensitive to detect this level (34) . The species differences observed could indicate that down-stream structural elements in mouse PrP retard the 40S ribosome to ensure that translational initiation is adequate, including when the initiator context is sub-optimal.
The observations of cytoplasmic PrP only in certain sub-sets of neurons (14;15) suggest that the cellular localization of PrP can vary between cell types, influenced by cellspecific factors that remain to be identified. Concerning the cell-specificity of the alternative translation initiation observed here for sheep PrP, similar data have been obtained with different cultured cell-types, such as canine kidney cells (MDCK), human neuroblastoma (SH-SY5Y), and colon cancer (LoVo) cells (36;47) , (data not shown). Thus, alternative translation initiation seems to operate constitutively in sheep PrP. However, our data cannot exclude that this process is subject to regulation. Several in vitro studies have shown that under normal conditions, a small portion of newly synthesized PrP, with apparently intact ER-SP, localize to the cytoplasm and is subject to proteasomal degradation (26;28) . Remarkably, inclusions of cytoplasmic PrP have been reported from rat pancreatic beta-cells, in particular from diabetes-prone animals and in response to experimental hyperglycemia (18) . It was speculated that this seemingly abnormal, but dynamically fluctuating, metabolism of PrP could contribute to physiological processes, related to blood glucose regulation, and not merely a pathological aberration (18) .
The full in vivo relevance of LRSdriven cytoplasmic generation of sheep PrP reported here remains to be established. One way of analyzing this further would be to generate transgenic mice carrying sheep PrP, with and without strong LRS, and compare the in vivo cellular handling of PrP in these, as well as the response to prion infectivity, upon experimental challenge. However, it is noteworthy that in a parallel and independent study to this report, Juanes and co-workers (35) found a nucleo-cytoplasmic localization of human and hamster PrP generated by internal translational start at Met 8 and Met 15 respectively. Moreover, they found that expression of a mutated hamster PrP with augmented translational start at Met 15 in CHO cells appeared to suppress cellular growth. We did not observe this phenomenon with any of the constructs reported here, regardless the level of cytoplasmic PrP, whether or not GFP had been inserted.
Inappropriate expression of cytoplasmic PrP in transgenic mice (22) or C. elegans (27) revealed severe neuropathological effects of the mislocalized PrPs, but results from cell culture studies of cytoplasmic PrP have been contradictory, with reports of high toxicity (22) , moderate toxicity (48), absence of toxcicity (49) , or even neuroprotective effects (20) . In order to evaluate the possible toxic interference of cytoplasmic PrP with the biogenesis of normal PrP, Norstrom and coworkers (29) (29) . Thus, although cytoplasmic PrPs have been shown to harbor pathogenic potential in transgenic models, possibly mediated through membrane perturbations (50) a significant role in the prion pathogenesis or replication seems unlikely.
LRS-driven production of a cytoplasmic sheep PrP surely constitutes a burden on the cell's capacity to dispose of mislocalized protein, which, even if occurring at very low levels, could create significant problems. A slight drop in the cells clearance of mislocalized protein could potentially lead to cytoplasmic build-up of PrP or PrPfragments, with the inherent risk of misfolding, aggregation and toxicity. However, in the cell culture models used here, no decrease in cellular viability or growth-rate could be observed, even under conditions of strong LRS. The possibility that LRS-generated cytoplasmic isoforms of PrP could be part of as yet undiscovered functional pathways for PrP, should not be excluded until properly explored.
In conclusion, we have discovered that sheep PrP mRNA displays a tendency to allow alternative translation initiation through LRS, in cell culture systems. This also operates when wild-type Kozak sequences surround the first start codon. Met 17 serves as the internal inframe alternative start codon, resulting in PrP with severely shortened ER-targeting peptide, which translocates poorly into the ER. This mechanism is probably also active in hamster and human PrP (35) , while it appears to occur at a much lower level in mouse PrP (34, and this report). Taken together, our data provide new insights into the intriguing observations of minor non-membranous cellular pathways for PrP. 
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